ASH: Gilead­'s CAR-T Yescar­ta holds up in more first-line lym­phoma pa­tients as part of ear­li­er use push

With the cell ther­a­py field large­ly piv­ot­ing to the next gen­er­a­tion of those drugs, es­tab­lished play­ers like Gilead’s Kite and Bris­tol My­ers Squibb are still carv­ing away at new routes in­to ear­li­er lines of care. This week­end, Kite churned out more da­ta for its CAR-T Yescar­ta in first-line lym­phoma pa­tients as part of a hope­ful push for a greater mar­ket share.

In up­dat­ed re­sults from the Phase II ZU­MA-12 study, Yescar­ta post­ed a 78% com­plete re­sponse rate among 37 pa­tients with high-risk large B cell lym­phoma at a me­di­an fol­low-up of just shy of 16 months, the drug­mak­ers said Mon­day at #ASH21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER